202 related articles for article (PubMed ID: 30834940)
21. Sunitinib-Induced Hypothyroidism and Survival in Pancreatic Neuroendocrine Tumors.
Mathew A; Führer D; Lahner H
Horm Metab Res; 2021 Dec; 53(12):794-800. PubMed ID: 34891209
[TBL] [Abstract][Full Text] [Related]
22. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509).
Capdevila J; Fazio N; Lopez C; Teulé A; Valle JW; Tafuto S; Custodio A; Reed N; Raderer M; Grande E; Garcia-Carbonero R; Jimenez-Fonseca P; Hernando J; Bongiovanni A; Spada F; Alonso V; Antonuzzo L; Spallanzani A; Berruti A; La Casta A; Sevilla I; Kump P; Giuffrida D; Merino X; Trejo L; Gajate P; Matos I; Lamarca A; Ibrahim T
J Clin Oncol; 2021 Jul; 39(20):2304-2312. PubMed ID: 33945297
[TBL] [Abstract][Full Text] [Related]
23. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
Mizuno Y; Kudo A; Akashi T; Akahoshi K; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tateishi U; Tanabe M
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1155-1163. PubMed ID: 29602973
[TBL] [Abstract][Full Text] [Related]
24. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.
Faivre S; Niccoli P; Castellano D; Valle JW; Hammel P; Raoul JL; Vinik A; Van Cutsem E; Bang YJ; Lee SH; Borbath I; Lombard-Bohas C; Metrakos P; Smith D; Chen JS; Ruszniewski P; Seitz JF; Patyna S; Lu DR; Ishak KJ; Raymond E
Ann Oncol; 2017 Feb; 28(2):339-343. PubMed ID: 27836885
[TBL] [Abstract][Full Text] [Related]
25. Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.
Vinik A; Bottomley A; Korytowsky B; Bang YJ; Raoul JL; Valle JW; Metrakos P; Hörsch D; Mundayat R; Reisman A; Wang Z; Chao RC; Raymond E
Target Oncol; 2016 Dec; 11(6):815-824. PubMed ID: 27924459
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
27. Assessment of the safety and efficiency of sunitinib malate in metastatic neuroendocrine tumours of the pancreas (NEN G1/G2) depending on the number and type of earlier therapeutic lines - initial report.
Wachuła E; Ćwikła JB; Rogowski W; Boratyn-Nowicka A; Szabłowska-Siwik S; Piątek M; Zemczak A; Michalik B; Jarząb B; Nawrocki S; Kos-Kudła B
Endokrynol Pol; 2014; 65(6):472-8. PubMed ID: 25554616
[TBL] [Abstract][Full Text] [Related]
28. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).
Grande E; Capdevila J; Castellano D; Teulé A; Durán I; Fuster J; Sevilla I; Escudero P; Sastre J; García-Donas J; Casanovas O; Earl J; Ortega L; Apellaniz-Ruiz M; Rodriguez-Antona C; Alonso-Gordoa T; Díez JJ; Carrato A; García-Carbonero R
Ann Oncol; 2015 Sep; 26(9):1987-1993. PubMed ID: 26063633
[TBL] [Abstract][Full Text] [Related]
29. Sunitinib in pancreatic neuroendocrine tumors.
Raymond E; Hammel P; Dreyer C; Maatescu C; Hentic O; Ruszniewski P; Faivre S
Target Oncol; 2012 Jun; 7(2):117-25. PubMed ID: 22661319
[TBL] [Abstract][Full Text] [Related]
30. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Mitry E; Walter T; Baudin E; Kurtz JE; Ruszniewski P; Dominguez-Tinajero S; Bengrine-Lefevre L; Cadiot G; Dromain C; Farace F; Rougier P; Ducreux M
Eur J Cancer; 2014 Dec; 50(18):3107-15. PubMed ID: 25454413
[TBL] [Abstract][Full Text] [Related]
31. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
Rogers JE; Lam M; Halperin DM; Dagohoy CG; Yao JC; Dasari A
Neuroendocrinology; 2022; 112(1):34-42. PubMed ID: 33434908
[TBL] [Abstract][Full Text] [Related]
32. Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study.
Smith D; Lepage C; Vicaut E; Dominguez S; Coriat R; Dubreuil O; Lecomte T; Baudin E; Venat Bouvet L; Samalin E; Santos A; Borie O; Bisot-Locard S; Goichot B; Lombard-Bohas C
Adv Ther; 2022 Jun; 39(6):2731-2748. PubMed ID: 35419649
[TBL] [Abstract][Full Text] [Related]
33. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors.
Strosberg JR; Chan JA; Ryan DP; Meyerhardt JA; Fuchs CS; Abrams T; Regan E; Brady R; Weber J; Campos T; Kvols LK; Kulke MH
Endocr Relat Cancer; 2013 Jun; 20(3):383-90. PubMed ID: 23572164
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.
Uemura H; Shinohara N; Yuasa T; Tomita Y; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H
Jpn J Clin Oncol; 2010 Mar; 40(3):194-202. PubMed ID: 19897852
[TBL] [Abstract][Full Text] [Related]
35. Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms.
Lee L; Ito T; Igarashi H; Ueda K; Fujiyama T; Kawabe K; Ogawa Y
J Hepatobiliary Pancreat Sci; 2017 Feb; 24(2):95-102. PubMed ID: 27926987
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
Barrios CH; Hernandez-Barajas D; Brown MP; Lee SH; Fein L; Liu JH; Hariharan S; Martell BA; Yuan J; Bello A; Wang Z; Mundayat R; Rha SY
Cancer; 2012 Mar; 118(5):1252-9. PubMed ID: 21898376
[TBL] [Abstract][Full Text] [Related]
37. Phase II open-label study of sunitinib in patients with advanced breast cancer.
Yardley DA; Dees EC; Myers SD; Li S; Healey P; Wang Z; Brickman MJ; Paolini J; Kern KA; Citrin DL
Breast Cancer Res Treat; 2012 Dec; 136(3):759-67. PubMed ID: 23073758
[TBL] [Abstract][Full Text] [Related]
38. Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial.
Xu J; Li J; Bai C; Xu N; Zhou Z; Li Z; Zhou C; Jia R; Lu M; Cheng Y; Mao C; Wang W; Cheng K; Su C; Hua Y; Qi C; Li J; Wang W; Li K; Sun Q; Ren Y; Su W
Clin Cancer Res; 2019 Jun; 25(12):3486-3494. PubMed ID: 30833272
[TBL] [Abstract][Full Text] [Related]
39. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
[TBL] [Abstract][Full Text] [Related]
40. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.
Lombard-Bohas C; Yao JC; Hobday T; Van Cutsem E; Wolin EM; Panneerselvam A; Stergiopoulos S; Shah MH; Capdevila J; Pommier R
Pancreas; 2015 Mar; 44(2):181-9. PubMed ID: 25479584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
